May #112 : Haartbeats - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

A Model Activist

Hep Cat

The Brave Lady of Haiti

Mighty Real

Big, Bad Media Bugout

Earthwatch

PEP on the Down Low

Quick Studies

Legal Eye

On the March!

Notes on Camp

Kentucky Fried Bigots?

POZ Picks

Hollywood to HIVers: Drop Dead

Ouch!

Veggie Table

Don't Run

A Peek in the Pipeline

Ducking Resistance

Quick Study

Pharm Team

Warning!

Haartbeats

Editor's Letter

Mailbox

Teen Jeopardy

Heavy Lifting



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

May 2005

Haartbeats

by Tim Murphy

Med-news nuggets from CROI, the year's biggest AIDS confab:

FAT FOLLIES  In two 2-year studies of arm and leg fat loss (lipoatrophy), ditching a multi-nuke combo for one with only a protease inhibitor (PI) and a non-nuke modestly restored fat—and still controlled HIV. • Another study found that replacing AZT or Zerit with Ziagen or Viread let HIVers regain a bit o’ fat over a year. Zerit has long been tied to fat loss, but “AZT’s getting the heat now” for milder cases, says treatment activist Nelson Vergel.

VIRAL VANQUISHERS  Countering critics of triple-nuke combos, Combivir (AZT + 3TC) plus Viread controlled most HIVers’ viral loads for about eight months in a small French study. • A San Fran study found that taking meds only 70 percent of the time controlled viral loads in HIVers on non-nuke–based regimens, but not in those on unboosted PI-based combos (likely because non-nukes last a loooong time in your body).

BEST TESTS  Two studies endorsed the effectiveness of checking blood levels of HIVers’ HAART meds, then  adjusting doses as needed—stoking the argument for therapeutic drug monitoring (TDM) • A study of HIVer women found that 36 percent who had normal cervical Pap smears turned up with abnormal anal Paps—reminding the ladies to have doc swab back there, too.



[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.